Home/ Stocks/ LRMR

Larimar Therapeutics, Inc. Common Stock

LRMR XNAS

$4.16 -0.12 (-2.86%) ▼ 15-min delayed

Open

$4.24

High

$4.28

Low

$4.08

Volume

631.2K

Market Cap

$436.31M

About Larimar Therapeutics, Inc. Common Stock

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 71 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$0	$-32,782,000	N/A
Q1 2026	$0	$-29,613,000	N/A
FY 2025	$0	$-165,673,000	N/A
Q3 2025	$0	$-47,712,000	$-0.61

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 3, 2026

Calendar →

TickerDaily Coverage

Why Is Larimar Therapeutics, Inc. Common Stock (LRMR) Stock Up 43.0% Today?

Market News David Brooks · Feb 25, 2026

Larimar Therapeutics (LRMR) stock rocketed 43.0% to $5.2368 on massive volume following securities...

View All Coverage →

Get LRMR Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Larimar Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.